Did You Miss Out on the Chance for Big Gains from Arcturus Stock?

Arcturus Therapeutics (NASDAQ: ARCT) soared 299% in 2020 as it advanced its coronavirus vaccine candidate into human trials. Investors were betting that the investigational mRNA vaccine would demonstrate efficacy to rival similar ones developed by bigger rivals Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).

Now the question is whether you missed out on your chance to profit from Arcturus' potential if you didn't invest early last year -- or if there could be more big share price gains to come.

Image source: Getty Images.

Continue reading

Source Fool.com